ArticleBioscience reports2022
CCNB2 is a novel prognostic factor and a potential therapeutic target in low-grade glioma.
Article in Bioscience reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 19 citations in OpenAlex.
- Article
- Platelet transcriptomic signatures in pediatric brain tumors distinguish cancer from cancer-free control.Acta neuropathologica communications · 2026Article
- Uncovering G Protein-Coupled Receptors: Novel Targets and Biomarkers for Predicting Glioma Prognosis.Annals of clinical and translational neurology · 2026Article
- Identification of hub genes and construction of a survival prediction model for patients with nasopharyngeal carcinoma.Scientific reports · 2026Article
- A comprehensive study integrating bioinformatics analysis and experimental results on HROB as a potential biomarker for the prognosis of lung adenocarcinoma.Scientific reports · 2026Article
- Article
- MCM4 as Potential Metastatic Biomarker in Lung Adenocarcinoma.Diagnostics (Basel, Switzerland) · 2025Article
- Origin recognition complex 6 overexpression promotes growth of glioma cells.Cell death & disease · 2024Article
- Deciphering the impact of circRNA-mediated autophagy on tumor therapeutic resistance: a novel perspective.Cellular & molecular biology letters · 2024Review
- Bioinformatics-based Identification of Ferroptosis-related Genes and their Diagnostic Value in Gestational Diabetes Mellitus.Endocrine, metabolic & immune disorders drug targets · 2024Article
- Transcriptome Analysis of Beta-Catenin-Related Genes in CD34+ Haematopoietic Stem and Progenitor Cells from Patients with AML.Mediterranean journal of hematology and infectious diseases · 2024Article
- Prognostic model of hepatocellular carcinoma based on cancer grade.World journal of clinical cases · 2023Article
- Identification of hub genes associated with bladder cancer using bioinformatic analyses.Translational cancer research · 2022Article
- Identification of biomarkers and key pathways in synovial sarcoma cells exposed to anlotinib by integrating bioinformatics analysis and experimental validation.American journal of translational research · 2022Article
- Glioma Subtypes Based on the Activity Changes of Immunologic and Hallmark Gene Sets in Cancer.Frontiers in endocrinology · 2022Article
- GPX8 as a Novel Prognostic Factor and Potential Therapeutic Target in Primary Glioma.Journal of immunology research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCyclin B2 (CCNB2) is an important component of the cyclin pathway and plays a key role in the occurrence and development of cancer. However, the correlation between prognosis of low-grade glioma (LGG), CCNB2, and tumor infiltrating lymphocytes is not clear.
methodsThe expression of CCNB2 in LGG was queried in Gene Expression Profiling Interactive Analysis 2 (GEPIA2) and TIMER databases. The relationships between CCNB2 and the clinicopathological features of LGG were analyzed using the Chinese Glioma Genome Atlas (CGGA) database. The relationship between CCNB2 expression and overall survival (OS) was evaluated by GEPIA2. The correlation between CCNB2 and LGG immune infiltration was analyzed by the TIMER database. Finally, quantitative real-time polymerase chain reaction (qRT-PCR) was performed to detect CCNB2 expression.
resultsThe expression of CCNB2 differed across different tumor tissues, but was higher in LGG than in normal tissues. LGG patients with high expression of CCNB2 have poorer prognosis. The expression of CCNB2 was correlated with age, WHO grade, IDH mutational status, 1p/19q codeletion status, and other clinicopathological features. The expression of CCNB2 in LGG was positively correlated with the infiltration level of B cells, dendritic cells, and macrophages. qRT-PCR results revealed that the expression of CCNB2 in LGG tissues was higher than normal tissues and higher expression of CCNB2 was associated with worse prognosis.
conclusionCCNB2 may be used as a potential biomarker to determine the prognosis of LGG and is also related to immune infiltration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.